Clinical Trials Logo

Scleroderma, Diffuse clinical trials

View clinical trials related to Scleroderma, Diffuse.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06029335 Active, not recruiting - Healthy Clinical Trials

Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases

Start date: September 1, 2020
Phase:
Study type: Observational

Objectives: Systemic autoimmune diseases are chronic diseases characterized by chronic inflammation, vasculopathy, and autoimmune phenomena. Several organ involvements are typical, including the central nervous system. Formerly published investigations emphasize a mild cognitive impairment affecting attention, memory, and complicated solution tasks. However, these symptoms significantly impact patients' routines and quality of life. The study examined the associations between cognitive impairment and clinical parameters regarding systemic autoimmune diseases. Methods: General clinical data, some serum biomarkers including CCl-18, YKL-40, COMP, VEGF, Galectin-3, and Pentraxin as well as results of functional, quality of life, and neuropsychological measures, the Mini-Mental State Examination (MMSE), the Digit Span Forward-Backward, the Trail making A, B and the Digit Symbol tests all were administered.

NCT ID: NCT05215431 Active, not recruiting - Periodontitis Clinical Trials

Antioxidant Profile in Patients With Systemic Sclerosis and Periodontitis

Start date: February 5, 2019
Phase:
Study type: Observational

The aim of the research will be to compare periodontal status and level of antioxidants in unstimulated saliva of systemic sclerosis patients with periodontitis and systemically healthy periodontitis patients. Twenty systemic sclerosis patients with periodontitis (SS group) and twenty systemically healthy periodontitis patients (P group) will be enrolled in the present study. The results may indicate higher periodontal destruction and antioxidant perturbations in unstimulated saliva of systemic sclerosis patients with periodontitis compared to systemically healthy periodontitis patients.

NCT ID: NCT05214794 Active, not recruiting - Systemic Sclerosis Clinical Trials

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

Start date: April 20, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.

NCT ID: NCT04927390 Active, not recruiting - Systemic Sclerosis Clinical Trials

Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

MINIMISE
Start date: December 8, 2021
Phase: Phase 2
Study type: Interventional

Systemic sclerosis or scleroderma is an autoimmune condition that cause thickening and hardening of the skin, but can also affect internal organs. There are two major subsets of scleroderma: the limited cutaneous systemic sclerosis (lcSSc) that usually affects the skin of the face, neck, lower legs or lower arms, but can also lead to internal organ complications, and the diffuse cutaneous systemic sclerosis (dcSSc) that may affect blood circulation and internal organs, as well as the skin. To date there is no drug that has been definitively proven to cure or modify the course of scleroderma. However, there is emerging evidence that immunosuppression and specifically mycophenolate mofetil (MMF) may be beneficial in lcSSc. The MINIMISE-Pilot trial would be an important first step to evaluate the risk and potential benefit to this disease group. MMF as the intervention of choice is both appropriate and timely, as it has been routinely used in the management of dcSSc. The aim of this pilot trial is to explore whether the immunosuppressive agent MMF can slow down disease progression in patients with lcSSc compared to the current standard of care alone. This pilot trial will also provide critical information for the development of a future large trial that could potentially transform lcSSc patient management.

NCT ID: NCT04683029 Active, not recruiting - Clinical trials for Scleroderma, Systemic

A Study of Guselkumab in Participants With Systemic Sclerosis

Start date: February 24, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).

NCT ID: NCT04650659 Active, not recruiting - Clinical trials for Pulmonary Arterial Hypertension

Functional Exercise Tests in Patients With Systemic Sclerosis

Start date: July 27, 2021
Phase:
Study type: Observational

The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as markers of pulmonary involvement in patients with SSc.

NCT ID: NCT04567537 Active, not recruiting - Scleroderma Clinical Trials

Laser Treatment for the Improvement of Scars and Scleroderma

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

In this study, the investigators seek to evaluate the effects of a laser treatment on the redistribution/regeneration of collagen on the clinical, microscopic, and molecular profiles of hypertrophic scars and scleroderma.

NCT ID: NCT04491396 Active, not recruiting - Scleroderma Clinical Trials

Yoga Adjunct for Scleroderma

GYYB
Start date: January 8, 2020
Phase: N/A
Study type: Interventional

This is a pilot research study to determine the feasibility of gentle yoga and breathing exercises for symptom management in patients with scleroderma. Participants will have a first study visit that includes completing demographic and quality-of-life surveys, learning the gentle yoga and breathing exercises, and providing two saliva samples before and after doing the exercises. After this visit, participants will do the gentle yoga and breathing exercises twice daily at home (morning and evening) by following a video hyperlink. Participants will make an entry in their Yoga Practice Diaries each time they practice at home. On the 12th Week, participants will return to MUSC for a final study visit that includes doing the gentle yoga and breathing exercises, providing saliva samples, and completing a satisfaction survey. There will be a total of 2 clinic visits (on Weeks 1 and 12). The study coordinator will telephone participants weekly during the 10 weeks that they do the gentle yoga and breathing exercises at home to answer questions and help solve any problems. Each visit will take about 2 hours for this research study, in addition to any routine clinical examinations. Each home yoga and breathing practice will take 1 hour. The total study duration is 12 Weeks (3 months). Participants will receive compensation for their travel in the form of prepaid Visa gift cards.

NCT ID: NCT04401943 Active, not recruiting - Systemic Sclerosis Clinical Trials

Online Fatigue Intervention Program for People With Scleroderma

FAME-ISS
Start date: May 13, 2020
Phase: N/A
Study type: Interventional

This research is being done to evaluate if an online fatigue intervention program will decrease fatigue, pain and increase confidence managing fatigue and being able to do daily tasks. This study involves competing a series of questionnaires before and after the intervention , and attending and participating in the online videoconference fatigue program for 1 1/2 hour meetings each week over a 6-week period of time.

NCT ID: NCT04368403 Active, not recruiting - Systemic Sclerosis Clinical Trials

A Study of KHK4827 in Patients With Systemic Sclerosis

Start date: October 6, 2017
Phase: Phase 1
Study type: Interventional

Exploratory evaluation of pharmacokinetics and safety of KHK4827 in subjects with systemic sclerosis